The online version of this article (doi:10.1007/s00259-017-3672-x) contains supplementary material, which is available to authorized users.
c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We investigated the feasibility of 89Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts.
In vitro membrane c-MET levels were determined by flow cytometry. HCC827ErlRes, an erlotinib-resistant clone with c-MET upregulation, was generated from the exon-19 EGFR-mutant human NSCLC cell line HCC827. Mice bearing HCC827 and HCC827ErlRes tumours in opposite flanks underwent 89Zr-onartuzumab PET scans. The HCC827-xenografted mice underwent 89Zr-onartuzumab PET scans before treatment and while receiving biweekly intraperitoneal injections of 100 mg/kg NVP-AUY-922 or vehicle. Ex vivo, tumour c-MET immunohistochemistry was correlated with the imaging results.
In vitro, membrane c-MET was upregulated in HCC827ErlRes tumours by 213 ± 44% in relation to the level in HCC827 tumours, while c-MET was downregulated by 69 ± 9% in HCC827 tumours following treatment with NVP-AUY-922. In vivo, 89Zr-onartuzumab uptake was 26% higher (P < 0.05) in erlotinib-resistant HCC827ErlRes than in HCC827 xenografts, while HCC827 tumour uptake was 33% lower (P < 0.001) following NVP-AUY-922 treatment.
The results show that 89Zr-onartuzumab PET effectively discriminates relevant changes in c-MET levels and could potentially be used clinically to monitor c-MET status.
Supplementary Fig. 1 a Efficiency of conjugation of Df to onartuzumab at various molar reaction ratios. b Radiochemical purity for 89Zr labelling at various Df to onartuzumab molar conjugation ratios, with specific activities between 50 and 1,000 MBq/mg conjugate. c Retained affinity of 89Zr-onartuzumab at various Df to onartuzumab molar conjugation ratios compared with that of naked onartuzumab in a competition assay. d Stability of 89Zr-onartuzumab in 0.9% NaCl at 4 °C, human serum at 37 °C and HEPES, pH 7.2 at 37° °C up to 7 days (PDF 38 kb)259_2017_3672_MOESM1_ESM.pdf
Supplementary Fig. 2 a Ex vivo organ uptake in HCC827 xenograft-bearing mice of 89Zr-onartuzumab 6 days after injection at protein doses of 10, 25 and 100 μg (six, five and four mice, respectively) and uptake of 89Zr-OA-NBC 6 days after injection at a protein dose of 10 μg. b Corresponding ex vivo organ uptake in HCC827 xenograft-bearing mice of 111In-OA-NBC 6 days after injection. Data are expressed as %ID/g ± SD (PDF 48 kb)259_2017_3672_MOESM2_ESM.pdf
Supplementary Fig. 3 Ex vivo organ uptake of 89Zr-onartuzumab and 111In-OA-NBC both 6 days after injection at a dose of 10 μg in ten HCC827 and HCC827ErlRes tumour-bearing mice. Data are expressed as %ID/g ± SD (PDF 35 kb)259_2017_3672_MOESM3_ESM.pdf
Supplementary Fig. 4 a Ex vivo organ uptake of 89Zr-onartuzumab 6 days after injection in six vehicle-treated and seven NVP-AUY-922-treated (at a dose of 100 mg/kg) HCC827 xenograft-bearing mice. b Corresponding ex vivo organ uptake of 111In-OA-NBC 6 days after injection in HCC827 xenograft-bearing mice. Data are expressed as %ID/g ± SD (PDF 42 kb)259_2017_3672_MOESM4_ESM.pdf
Supplementary Fig. 5 Histological grading of necrosis (H&E staining) of (a) HCC827 and HCC827ErlRes tumours and (b) vehicle-treated and NVP-AUY-922-treated HCC827 tumours, where score 0+ represents 0–5% necrosis, 1+ 5–15% necrosis, 2+ 15–25% necrosis, 3+ 25–35% necrosis and 4+ >35% necrosis. (PDF 25 kb)259_2017_3672_MOESM5_ESM.pdf
Supplementary Fig. 6 Correlation between ex vivo 89Zr-onartuzumab/89Zr-OACD8 tumour uptake (%ID/g) and in vivo PET tumour uptake (SUVmean). (PDF 31 kb)259_2017_3672_MOESM6_ESM.pdf
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib ± onartuzumab in advanced non-small-cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 2014;20:4488–4499. CrossRefPubMedPubMedCentral
Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, et al. Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33:1666–1673. CrossRefPubMedPubMedCentral
Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2014;32:5s, 2014 (suppl; abstract 8000).
de Vries EG, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ, et al. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 1989;49:4175–4178. PubMed
Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–1281. PubMed
Ruegg CL, Anderson-berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221–4226. PubMed
Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, et al. Imaging the Met receptor tyrosine kinase (Met) and assessing tumor responses to a Met tyrosine kinase inhibitor in human xenograft mouse models with a (99mTc) (AH-113018) or Cy 5** (AH-112543) labeled peptide. Mol Imaging. 2015;14:499–515. PubMed
Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SBM, et al. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. Eur J Cancer. 2014;50:2508–2516. CrossRefPubMed
van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18:6306–6314. CrossRefPubMed
- 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
Anton G. T. Terwisscha van Scheltinga
Elisabeth G. E. de Vries
Marjolijn N. Lub-de Hooge
- Springer Berlin Heidelberg
- European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089